{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T09:09:08Z","timestamp":1780304948633,"version":"3.54.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr HIV\/AIDS Rep"],"DOI":"10.1007\/s11904-026-00786-z","type":"journal-article","created":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T08:44:38Z","timestamp":1780303478000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Central Nervous System HIV Persistence and Clinical Consequences During Suppressive ART"],"prefix":"10.1007","volume":"23","author":[{"given":"Kathryn B.","family":"Holroyd","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Spudich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Winston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam","family":"Nightingale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,1]]},"reference":[{"issue":"5","key":"786_CR1","doi-asserted-by":"publisher","first-page":"e343","DOI":"10.1016\/S2352-3018(23)00012-7","volume":"10","author":"K Govender","year":"2023","unstructured":"Govender K, Nyamaruze P, Cowden RG, Pillay Y, Bekker LG. Children and young women in eastern and southern Africa are key to meeting 2030 HIV targets: time to accelerate action. Lancet HIV. 2023;10(5):e343\u201350. https:\/\/doi.org\/10.1016\/S2352-3018(23)00012-7.","journal-title":"Lancet HIV"},{"issue":"3","key":"786_CR2","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s40506-020-00228-3","volume":"12","author":"KB Holroyd","year":"2020","unstructured":"Holroyd KB, Vishnevetsky A, Srinivasan M, Saylor D. Neurologic complications of acute HIV infection. Curr Treat Options Infect Dis. 2020;12(3):227\u201342. https:\/\/doi.org\/10.1007\/s40506-020-00228-3.","journal-title":"Curr Treat Options Infect Dis"},{"issue":"2","key":"786_CR3","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.immuni.2007.01.007","volume":"26","author":"F Hladik","year":"2007","unstructured":"Hladik F, et al. Initial events in establishing vaginal entry and infection by human immunodeficiency virus type-1. Immunity. 2007;26(2):257\u201370. https:\/\/doi.org\/10.1016\/j.immuni.2007.01.007.","journal-title":"Immunity"},{"issue":"1","key":"786_CR4","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s12981-023-00511-5","volume":"20","author":"R Bai","year":"2023","unstructured":"Bai R, et al. Role of microglia in HIV-1 infection. AIDS Res Ther. 2023;20(1):16. https:\/\/doi.org\/10.1186\/s12981-023-00511-5.","journal-title":"AIDS Res Ther"},{"issue":"5","key":"786_CR5","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1002\/JLB.5VMR0122-046RRR","volume":"112","author":"MM N\u00fchn","year":"2022","unstructured":"N\u00fchn MM, et al. Shock and kill within the CNS: a promising HIV eradication approach? J Leukoc Biol. 2022;112(5):1297\u2013315. https:\/\/doi.org\/10.1002\/JLB.5VMR0122-046RRR.","journal-title":"J Leukoc Biol"},{"issue":"7","key":"786_CR6","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1086\/343768","volume":"186","author":"JE Clements","year":"2002","unstructured":"Clements JE, et al. The central nervous system as a reservoir for simian immunodeficiency virus (SIV): steady-state levels of SIV DNA in brain from acute through asymptomatic infection. J Infect Dis. 2002;186(7):905\u201313. https:\/\/doi.org\/10.1086\/343768.","journal-title":"J Infect Dis"},{"issue":"2","key":"786_CR7","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1093\/infdis\/jis326","volume":"206","author":"V Valcour","year":"2012","unstructured":"Valcour V, et al. Central nervous system viral invasion and inflammation during acute HIV infection. J Infect Dis. 2012;206(2):275\u201382. https:\/\/doi.org\/10.1093\/infdis\/jis326.","journal-title":"J Infect Dis"},{"issue":"1","key":"786_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s12977-017-0344-7","volume":"14","author":"M Ara\u00ednga","year":"2017","unstructured":"Ara\u00ednga M, Edagwa B, Mosley RL, Poluektova LY, Gorantla S, Gendelman HE. A mature macrophage is a principal HIV-1 cellular reservoir in humanized mice after treatment with long acting antiretroviral therapy. Retrovirology. 2017;14(1):17. https:\/\/doi.org\/10.1186\/s12977-017-0344-7.","journal-title":"Retrovirology"},{"issue":"1","key":"786_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2016.467","volume":"8","author":"AS Saribas","year":"2017","unstructured":"Saribas AS, Cicalese S, Ahooyi TM, Khalili K, Amini S, Sariyer IK. HIV-1 Nef is released in extracellular vesicles derived from astrocytes: evidence for Nef-mediated neurotoxicity. Cell Death Dis. 2017;8(1):e2542. https:\/\/doi.org\/10.1038\/cddis.2016.467.","journal-title":"Cell Death Dis"},{"issue":"3","key":"786_CR10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1004720","volume":"11","author":"CB Sturdevant","year":"2015","unstructured":"Sturdevant CB, Joseph SB, Schnell G, Price RW, Swanstrom R, Spudich S. Compartmentalized replication of R5 T cell-tropic HIV-1 in the central nervous system early in the course of infection. PLoS Pathog. 2015;11(3):e1004720. https:\/\/doi.org\/10.1371\/journal.ppat.1004720.","journal-title":"PLoS Pathog"},{"key":"786_CR11","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/j.ebiom.2019.06.020","volume":"45","author":"MM Elsheikh","year":"2019","unstructured":"Elsheikh MM, Tang Y, Li D, Jiang G. Deep latency: a new insight into a functional HIV cure. EBioMedicine. 2019;45:624\u20139. https:\/\/doi.org\/10.1016\/j.ebiom.2019.06.020.","journal-title":"EBioMedicine"},{"key":"786_CR12","doi-asserted-by":"publisher","DOI":"10.1172\/JCI167417","author":"Y Tang","year":"2023","unstructured":"Tang Y, et al. Brain microglia serve as a persistent HIV reservoir despite durable antiretroviral therapy. J Clin Invest. 2023. https:\/\/doi.org\/10.1172\/JCI167417.","journal-title":"J Clin Invest"},{"key":"786_CR13","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.89837","author":"W Sun","year":"2023","unstructured":"Sun W, et al. Persistence of intact HIV-1 proviruses in the brain during antiretroviral therapy. Elife. 2023. https:\/\/doi.org\/10.7554\/eLife.89837.","journal-title":"Elife"},{"issue":"8","key":"786_CR14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1012446","volume":"20","author":"J Jamal Eddine","year":"2024","unstructured":"Jamal Eddine J, et al. HIV transcription persists in the brain of virally suppressed people with HIV. PLoS Pathog. 2024;20(8):e1012446. https:\/\/doi.org\/10.1371\/journal.ppat.1012446.","journal-title":"PLoS Pathog"},{"issue":"15","key":"786_CR15","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1097\/QAD.0000000000001950","volume":"32","author":"G Ulfhammer","year":"2018","unstructured":"Ulfhammer G, et al. Persistent central nervous system immune activation following more than 10 years of effective HIV antiretroviral treatment. AIDS. 2018;32(15):2171\u20138. https:\/\/doi.org\/10.1097\/QAD.0000000000001950.","journal-title":"AIDS"},{"key":"786_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1570692","volume":"16","author":"SJ Byrnes","year":"2025","unstructured":"Byrnes SJ, et al. Neuroinflammation associated with proviral DNA persists in the brain of virally suppressed people with HIV. Front Immunol. 2025;16:1570692. https:\/\/doi.org\/10.3389\/fimmu.2025.1570692.","journal-title":"Front Immunol"},{"issue":"8","key":"786_CR17","doi-asserted-by":"publisher","first-page":"3339","DOI":"10.1172\/JCI127413","volume":"129","author":"S Spudich","year":"2019","unstructured":"Spudich S, et al. Persistent HIV-infected cells in cerebrospinal fluid are associated with poorer neurocognitive performance. J Clin Invest. 2019;129(8):3339\u201346. https:\/\/doi.org\/10.1172\/JCI127413.","journal-title":"J Clin Invest"},{"issue":"Suppl 2","key":"786_CR18","doi-asserted-by":"publisher","first-page":"S107","DOI":"10.1097\/QAD.0000000000002252","volume":"33","author":"A Winston","year":"2019","unstructured":"Winston A, et al. Defining cerebrospinal fluid HIV RNA escape: editorial review AIDS. AIDS. 2019;33(Suppl 2):S107\u201311. https:\/\/doi.org\/10.1097\/QAD.0000000000002252.","journal-title":"AIDS"},{"issue":"2","key":"786_CR19","doi-asserted-by":"publisher","first-page":"e429","DOI":"10.1093\/infdis\/jiae555","volume":"231","author":"G Ulfhammer","year":"2025","unstructured":"Ulfhammer G, et al. Asymptomatic cerebrospinal fluid HIV-1 escape: incidence and consequences. J Infect Dis. 2025;231(2):e429\u201337. https:\/\/doi.org\/10.1093\/infdis\/jiae555.","journal-title":"J Infect Dis"},{"key":"786_CR20","doi-asserted-by":"publisher","DOI":"10.1172\/JCI176358","author":"LP Kincer","year":"2024","unstructured":"Kincer LP, et al. Neurosymptomatic HIV-1 CSF escape is associated with replication in CNS T cells and inflammation. J Clin Invest. 2024. https:\/\/doi.org\/10.1172\/JCI176358.","journal-title":"J Clin Invest"},{"issue":"14","key":"786_CR21","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1097\/QAD.0b013e328355e6b2","volume":"26","author":"MJ Peluso","year":"2012","unstructured":"Peluso MJ, et al. Cerebrospinal fluid HIV escape associated with progressive neurologic dysfunction in patients on antiretroviral therapy with well controlled plasma viral load. AIDS. 2012;26(14):1765\u201374. https:\/\/doi.org\/10.1097\/QAD.0b013e328355e6b2.","journal-title":"AIDS"},{"issue":"5","key":"786_CR22","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1007\/s11904-020-00526-x","volume":"17","author":"F Ferretti","year":"2020","unstructured":"Ferretti F, et al. Relapse of symptomatic cerebrospinal fluid HIV escape. Curr HIV\/AIDS Rep. 2020;17(5):522\u20138. https:\/\/doi.org\/10.1007\/s11904-020-00526-x.","journal-title":"Curr HIV\/AIDS Rep"},{"issue":"8","key":"786_CR23","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1093\/cid\/ciy267","volume":"67","author":"SS Mukerji","year":"2018","unstructured":"Mukerji SS, et al. Impact of antiretroviral regimens on cerebrospinal fluid viral escape in a prospective multicohort study of antiretroviral therapy-experienced Human Immunodeficiency Virus-1-infected adults in the United States. Clin Infect Dis. 2018;67(8):1182\u201390. https:\/\/doi.org\/10.1093\/cid\/ciy267.","journal-title":"Clin Infect Dis"},{"key":"786_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci8100190","author":"DA Collier","year":"2018","unstructured":"Collier DA, Haddow L, Brijkumar J, Moosa MS, Benjamin L, Gupta RK. HIV cerebrospinal fluid escape and neurocognitive pathology in the era of combined antiretroviral therapy: What lies beneath the tip of the iceberg in Sub-Saharan Africa? Brain Sci. 2018. https:\/\/doi.org\/10.3390\/brainsci8100190.","journal-title":"Brain Sci"},{"issue":"12","key":"786_CR25","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1093\/infdis\/jiw454","volume":"214","author":"A Ed\u00e9n","year":"2016","unstructured":"Ed\u00e9n A, et al. Asymptomatic cerebrospinal fluid HIV-1 viral blips and viral escape during antiretroviral therapy: A longitudinal study. J Infect Dis. 2016;214(12):1822\u20135. https:\/\/doi.org\/10.1093\/infdis\/jiw454.","journal-title":"J Infect Dis"},{"issue":"2","key":"786_CR26","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1007\/s11904-015-0267-7","volume":"12","author":"F Ferretti","year":"2015","unstructured":"Ferretti F, Gisslen M, Cinque P, Price RW. Cerebrospinal fluid HIV escape from antiretroviral therapy. Curr HIV\/AIDS Rep. 2015;12(2):280\u20138. https:\/\/doi.org\/10.1007\/s11904-015-0267-7.","journal-title":"Curr HIV\/AIDS Rep"},{"issue":"1","key":"786_CR27","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3109\/13550280903514776","volume":"16","author":"SM de Almeida","year":"2010","unstructured":"de Almeida SM, et al. Cerebrospinal fluid Human Immunodeficiency Virus viral load in patients with neurosyphilis. J Neurovirol. 2010;16(1):6\u201312. https:\/\/doi.org\/10.3109\/13550280903514776.","journal-title":"J Neurovirol"},{"issue":"5","key":"786_CR28","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1080\/003655401750174309","volume":"33","author":"O Moling","year":"2001","unstructured":"Moling O, Rossi P, Rimenti G, Vedovelli C, Mian P. Varicella-zoster virus meningitis and cerebrospinal fluid HIV RNA. Scand J Infect Dis. 2001;33(5):398\u20139. https:\/\/doi.org\/10.1080\/003655401750174309.","journal-title":"Scand J Infect Dis"},{"issue":"12","key":"786_CR29","doi-asserted-by":"publisher","first-page":"1936","DOI":"10.1093\/infdis\/jir667","volume":"204","author":"V Dahl","year":"2011","unstructured":"Dahl V, et al. Raltegravir treatment intensification does not alter cerebrospinal fluid HIV-1 infection or immunoactivation in subjects on suppressive therapy. J Infect Dis. 2011;204(12):1936\u201345. https:\/\/doi.org\/10.1093\/infdis\/jir667.","journal-title":"J Infect Dis"},{"issue":"5","key":"786_CR30","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1097\/QAI.0b013e3181f5b3d1","volume":"55","author":"A Yilmaz","year":"2010","unstructured":"Yilmaz A, et al. Treatment intensification has no effect on the HIV-1 central nervous system infection in patients on suppressive antiretroviral therapy. J Acquir Immune Defic Syndr. 2010;55(5):590\u20136. https:\/\/doi.org\/10.1097\/QAI.0b013e3181f5b3d1.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"1","key":"786_CR31","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1097\/QAD.0000000000003379","volume":"37","author":"LD Keng","year":"2023","unstructured":"Keng LD, Winston A, Sabin CA. The global burden of cognitive impairment in people with HIV. AIDS. 2023;37(1):61\u201370. https:\/\/doi.org\/10.1097\/QAD.0000000000003379.","journal-title":"AIDS"},{"issue":"5","key":"786_CR32","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1097\/QAI.0b013e31827f1bdb","volume":"62","author":"BB Gelman","year":"2013","unstructured":"Gelman BB, et al. Neurovirological correlation with HIV-associated neurocognitive disorders and encephalitis in a HAART-era cohort. J Acquir Immune Defic Syndr. 2013;62(5):487\u201395. https:\/\/doi.org\/10.1097\/QAI.0b013e31827f1bdb.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"786_CR33","doi-asserted-by":"publisher","first-page":"312","DOI":"10.12688\/f1000research.10651.1","volume":"6","author":"A Carroll","year":"2017","unstructured":"Carroll A, Brew B. HIV-associated neurocognitive disorders: recent advances in pathogenesis, biomarkers, and treatment. F1000Res. 2017;6:312. https:\/\/doi.org\/10.12688\/f1000research.10651.1.","journal-title":"F1000Res"},{"issue":"4","key":"786_CR34","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1111\/hiv.13411","volume":"24","author":"LT Le","year":"2023","unstructured":"Le LT, et al. Correlation between CD4\/CD8 ratio and neurocognitive performance during early HIV infection. HIV Med. 2023;24(4):442\u201352. https:\/\/doi.org\/10.1111\/hiv.13411.","journal-title":"HIV Med"},{"issue":"3","key":"786_CR35","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1093\/cid\/ciy501","volume":"68","author":"J Gutierrez","year":"2019","unstructured":"Gutierrez J, Byrd D, Yin MT, Morgello S. Relationship between brain arterial pathology and neurocognitive performance among individuals with human immunodeficiency virus. Clin Infect Dis. 2019;68(3):490\u20137. https:\/\/doi.org\/10.1093\/cid\/ciy501.","journal-title":"Clin Infect Dis"},{"key":"786_CR36","doi-asserted-by":"publisher","unstructured":"Saylor D et al. HIV-associated neurocognitive disorder - pathogenesis and prospects for treatment, (in eng).\u00a0Nat Rev Neurol. 2016; 12(5): 309.\u00a0https:\/\/doi.org\/10.1038\/nrneurol.2016.53","DOI":"10.1038\/nrneurol.2016.53"},{"issue":"7","key":"786_CR37","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1097\/QAD.0000000000002193","volume":"33","author":"R Sanford","year":"2019","unstructured":"Sanford R, et al. HIV infection and cerebral small vessel disease are independently associated with brain atrophy and cognitive impairment. AIDS. 2019;33(7):1197\u2013205. https:\/\/doi.org\/10.1097\/QAD.0000000000002193.","journal-title":"AIDS"},{"issue":"9","key":"786_CR38","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1056\/NEJMoa1506816","volume":"373","author":"JD Lundgren","year":"2015","unstructured":"Lundgren JD, et al. Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection, (in eng). N Engl J Med. 2015;373(9):795\u2013807. https:\/\/doi.org\/10.1056\/NEJMoa1506816.","journal-title":"N Engl J Med"},{"issue":"8","key":"786_CR39","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1097\/QAD.0000000000001778","volume":"32","author":"EJ Wright","year":"2018","unstructured":"Wright EJ, et al. No neurocognitive advantage for immediate antiretroviral treatment in adults with greater than 500 CD4\u2009+\u2009T-cell counts. AIDS. 2018;32(8):985\u201397. https:\/\/doi.org\/10.1097\/QAD.0000000000001778.","journal-title":"AIDS"},{"issue":"6","key":"786_CR40","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1093\/cid\/ciaa167","volume":"72","author":"JR Lama","year":"2021","unstructured":"Lama JR, et al. Clinical and immunologic outcomes after immediate or deferred antiretroviral therapy initiation during primary Human Immunodeficiency Virus infection: the Sabes randomized clinical study. Clin Infect Dis. 2021;72(6):1042\u201350. https:\/\/doi.org\/10.1093\/cid\/ciaa167.","journal-title":"Clin Infect Dis"},{"key":"786_CR41","unstructured":"Robertson K et al. Can we afford to wait? ART and the CNS., ed. Presented at the conferences on retroviruses and opportunistic infections, 2017."},{"issue":"11","key":"786_CR42","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1080\/09540121.2022.2098231","volume":"35","author":"AJ Webb","year":"2023","unstructured":"Webb AJ, Borrelli EP, Vyas A, Taylor LE, Buchanan AL. The effect of antiretroviral therapy with high central nervous system penetration on HIV-related cognitive impairment: a systematic review and meta-analysis. AIDS Care. 2023;35(11):1635\u201346. https:\/\/doi.org\/10.1080\/09540121.2022.2098231.","journal-title":"AIDS Care"},{"issue":"6","key":"786_CR43","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1093\/cid\/ciad265","volume":"77","author":"SL Letendre","year":"2023","unstructured":"Letendre SL, et al. Antiretroviral therapy intensification for neurocognitive impairment in Human Immunodeficiency Virus. Clin Infect Dis. 2023;77(6):866\u201374. https:\/\/doi.org\/10.1093\/cid\/ciad265.","journal-title":"Clin Infect Dis"},{"issue":"7","key":"786_CR44","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1038\/s41582-023-00813-2","volume":"19","author":"S Nightingale","year":"2023","unstructured":"Nightingale S, et al. Cognitive impairment in people living with HIV: consensus recommendations for a new approach. Nat Rev Neurol. 2023;19(7):424\u201333. https:\/\/doi.org\/10.1038\/s41582-023-00813-2.","journal-title":"Nat Rev Neurol"},{"issue":"7","key":"786_CR45","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1038\/s41591-018-0026-6","volume":"24","author":"DJ Colby","year":"2018","unstructured":"Colby DJ, et al. Rapid HIV RNA rebound after antiretroviral treatment interruption in persons durably suppressed in Fiebig I acute HIV infection. Nat Med. 2018;24(7):923\u20136. https:\/\/doi.org\/10.1038\/s41591-018-0026-6.","journal-title":"Nat Med"},{"key":"786_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.coviro.2019.03.004","volume":"38","author":"JM Zerbato","year":"2019","unstructured":"Zerbato JM, Purves HV, Lewin SR, Rasmussen TA. Between a shock and a hard place: challenges and developments in HIV latency reversal. Curr Opin Virol. 2019;38:1\u20139. https:\/\/doi.org\/10.1016\/j.coviro.2019.03.004.","journal-title":"Curr Opin Virol"},{"issue":"1","key":"786_CR47","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofv037","volume":"2","author":"TA Rasmussen","year":"2015","unstructured":"Rasmussen TA, et al. Activation of latent Human Immunodeficiency Virus by the histone deacetylase inhibitor panobinostat: a pilot study to assess effects on the central nervous system. Open Forum Infect Dis. 2015;2(1):ofv037. https:\/\/doi.org\/10.1093\/ofid\/ofv037.","journal-title":"Open Forum Infect Dis"},{"issue":"3","key":"786_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.jve.2020.100004","volume":"6","author":"EDMB Kroon","year":"2020","unstructured":"Kroon EDMB, et al. A randomized trial of vorinostat with treatment interruption after initiating antiretroviral therapy during acute HIV-1 infection. J Virus Erad. 2020;6(3):100004. https:\/\/doi.org\/10.1016\/j.jve.2020.100004.","journal-title":"J Virus Erad"},{"issue":"7","key":"786_CR49","doi-asserted-by":"publisher","first-page":"e1885","DOI":"10.1093\/cid\/ciaa1344","volume":"73","author":"J Hellmuth","year":"2021","unstructured":"Hellmuth J, et al. Central nervous system safety during brief analytic treatment interruption of antiretroviral therapy within 4 Human Immunodeficiency Virus remission trials: An observational study in acutely treated people living with Human Immunodeficiency Virus. Clin Infect Dis. 2021;73(7):e1885\u201392. https:\/\/doi.org\/10.1093\/cid\/ciaa1344.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"786_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-59398-7","volume":"16","author":"E Pellaers","year":"2025","unstructured":"Pellaers E, et al. BRD4 modulator ZL0580 and LEDGINs additively block and lock HIV-1 transcription. Nat Commun. 2025;16(1):4226. https:\/\/doi.org\/10.1038\/s41467-025-59398-7.","journal-title":"Nat Commun"},{"issue":"1","key":"786_CR51","doi-asserted-by":"publisher","DOI":"10.1186\/s12981-025-00734-8","volume":"22","author":"S Mahomed","year":"2025","unstructured":"Mahomed S, et al. Clinical trials of broadly neutralizing monoclonal antibodies in people living with HIV - a review. AIDS Res Ther. 2025;22(1):44. https:\/\/doi.org\/10.1186\/s12981-025-00734-8.","journal-title":"AIDS Res Ther"},{"issue":"2","key":"786_CR52","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/s41591-019-0747-1","volume":"26","author":"J Niessl","year":"2020","unstructured":"Niessl J, et al. Combination anti-HIV-1 antibody therapy is associated with increased virus-specific T cell immunity. Nat Med. 2020;26(2):222\u20137. https:\/\/doi.org\/10.1038\/s41591-019-0747-1.","journal-title":"Nat Med"},{"issue":"10","key":"786_CR53","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofy242","volume":"5","author":"SA Riddler","year":"2018","unstructured":"Riddler SA, et al. Randomized clinical trial to assess the impact of the broadly neutralizing HIV-1 monoclonal antibody VRC01 on HIV-1 persistence in individuals on effective ART. Open Forum Infect Dis. 2018;5(10):ofy242. https:\/\/doi.org\/10.1093\/ofid\/ofy242.","journal-title":"Open Forum Infect Dis"},{"issue":"5","key":"786_CR54","doi-asserted-by":"publisher","first-page":"e297","DOI":"10.1016\/S2352-3018(19)30053-0","volume":"6","author":"TA Crowell","year":"2019","unstructured":"Crowell TA, et al. Safety and efficacy of VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV397): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet HIV. 2019;6(5):e297\u2013306. https:\/\/doi.org\/10.1016\/S2352-3018(19)30053-0.","journal-title":"Lancet HIV"},{"issue":"6","key":"786_CR55","doi-asserted-by":"publisher","first-page":"3299","DOI":"10.1172\/JCI134395","volume":"130","author":"EM Cale","year":"2020","unstructured":"Cale EM, et al. Neutralizing antibody VRC01 failed to select for HIV-1 mutations upon viral rebound. J Clin Invest. 2020;130(6):3299\u2013304. https:\/\/doi.org\/10.1172\/JCI134395.","journal-title":"J Clin Invest"},{"key":"786_CR56","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1056\/NEJMoa1608243","volume":"375","author":"KJ Bar","year":"2016","unstructured":"Bar KJ, et al. Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption, (in eng). N Engl J Med. 2016;375:2037\u201350. https:\/\/doi.org\/10.1056\/NEJMoa1608243.","journal-title":"N Engl J Med"},{"issue":"7913","key":"786_CR57","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1038\/s41586-022-04597-1","volume":"606","author":"C Gaebler","year":"2022","unstructured":"Gaebler C, et al. Prolonged viral suppression with anti-HIV-1 antibody therapy. Nature. 2022;606(7913):368\u201374. https:\/\/doi.org\/10.1038\/s41586-022-04597-1.","journal-title":"Nature"},{"key":"786_CR58","unstructured":"Prabhakaran M et al. Infiltration of VRC01 Into the Cerebrospinal fluid in humans in the RV397 Study, ed. Conference on Retroviruses and opportunistic Infections. Boston., 2020."},{"issue":"3","key":"786_CR59","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1097\/COH.0000000000000847","volume":"19","author":"A Mastrangelo","year":"2024","unstructured":"Mastrangelo A, Gama L, Cinque P. Strategies to target the central nervous system HIV reservoir. Curr Opin HIV AIDS. 2024;19(3):133\u201340. https:\/\/doi.org\/10.1097\/COH.0000000000000847.","journal-title":"Curr Opin HIV AIDS"},{"issue":"7","key":"786_CR60","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1056\/NEJMoa0802905","volume":"360","author":"G H\u00fctter","year":"2009","unstructured":"H\u00fctter G, et al. Long-term control of HIV by CCR5 Delta32\/Delta32 stem-cell transplantation. N Engl J Med. 2009;360(7):692\u20138. https:\/\/doi.org\/10.1056\/NEJMoa0802905.","journal-title":"N Engl J Med"},{"issue":"5","key":"786_CR61","doi-asserted-by":"publisher","first-page":"e340","DOI":"10.1016\/S2352-3018(20)30069-2","volume":"7","author":"RK Gupta","year":"2020","unstructured":"Gupta RK, et al. Evidence for HIV-1 cure after CCR5\u039432\/\u039432 allogeneic haemopoietic stem-cell transplantation 30 months post analytical treatment interruption: a case report. Lancet HIV. 2020;7(5):e340\u20137. https:\/\/doi.org\/10.1016\/S2352-3018(20)30069-2.","journal-title":"Lancet HIV"}],"container-title":["Current HIV\/AIDS Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11904-026-00786-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11904-026-00786-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11904-026-00786-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T08:44:40Z","timestamp":1780303480000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11904-026-00786-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,1]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["786"],"URL":"https:\/\/doi.org\/10.1007\/s11904-026-00786-z","relation":{},"ISSN":["1548-3576"],"issn-type":[{"value":"1548-3576","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,1]]},"assertion":[{"value":"8 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human or animal subjects performed by any\u00a0of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"17"}}